Next for Addyi drugmaker: Eliminating the stigma over low female sex drive

Sprout Pharmaceuticals CEO Cindy Whitehead isn't in the business of treating mental illness. Her company's drug, Addyi, was approved this week by the FDA to treat low sexual desire in women, also known as hypoactive sexual dysfunction disorder, or HSDD. But she finds herself thinking about early conversations around mental illness quite a bit, in the context of all the conversations she's having around her drug and its intended use. "There are a lot of parallels," she told me Thursday. Both mental…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news